Stay informed about breakthrough discoveries in Lgenia research for Tuberculosis, Malaria, Alzheimer's disease, and Women's Health.
Indiana University School of Medicine researchers, in partnership with Lgenia, have identified a portfolio of novel drug targets that may accelerate promising treatments for patients living with Alzheimer’s disease.
Read Full Article→
In early 2022, the Gates Foundation awarded a grant to the University of Ghana, NMIMR, and KNUST to establish a collaborative drug discovery program. Lgenia mentored the Ghanaian team, and in February 2023, Dr. Miles Siegel visited Africa for a multi-institutional check-in.
Read Full Article→
The TB Drug Accelerator (TBDA) marks a decade of collaborative research, accelerating the discovery of new treatments for tuberculosis. Lgenia contributed to milestone studies, helping to identify promising compounds.
Read Full Article→
In 2020, Lgenia partnered with Indiana University to accelerate Alzheimer's research, combining expertise in medicinal chemistry and neurobiology. The collaboration aims to discover new therapies for patients.
Read Full Article→
In 2018, Lgenia joined the TB Drug Accelerator, a global partnership to fast-track the development of new tuberculosis treatments. Our team contributed to early-stage research and compound screening.
Read Full Article→